100 Participants Needed

Exparel for Post-Surgery Pain Management in Thyroid Conditions

Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: University of Missouri-Columbia
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the drug Bupivacaine Hydrochloride-EPINEPHrine for post-surgery pain management in thyroid conditions?

Research shows that using bupivacaine with epinephrine after thyroid surgery can help reduce pain and the need for additional pain medication. This suggests that the drug may be effective for managing post-surgery pain in thyroid conditions.12345

Is Exparel safe for managing post-surgery pain?

Liposome bupivacaine (Exparel) has been studied for safety in clinical trials, showing it is generally safe for use in managing post-surgical pain when administered as a single dose at the surgical site.12456

How does the drug Exparel differ from other treatments for post-surgery pain management in thyroid conditions?

Exparel is unique because it is an extended-release local anesthetic that provides long-lasting pain relief with a single injection at the surgical site, reducing the need for opioids and potentially leading to fewer side effects. This approach is different from traditional pain management methods that often require multiple doses and higher opioid use.678910

What is the purpose of this trial?

The question proposed by this study, is one of patient outcomes. Does intraoperative injection of Exparel decrease postoperative use of opioid pain medications in patients undergoing thyroid and parathyroid surgery? The trial seeks to assess the effect that Exparel has on postoperative pain control.

Research Team

TG

Tabitha Galloway, MD

Principal Investigator

University of Missouri Department of Otolaryngology-Head and Neck Surgery

Eligibility Criteria

This trial is for English-speaking adults over 18 who need thyroid or parathyroid surgery. It's not open to those under 18, with a history of opioid abuse, or allergies to local anesthetics or opioids.

Inclusion Criteria

I need surgery for my parathyroid or thyroid as recommended by my doctor.
I am over 18 years old.
English as primary language

Exclusion Criteria

I am under 18 years old.
You have a history of misusing opioid medications.
You have a real allergy to any local numbing medicine.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo thyroid or parathyroid surgery with different local anesthetic protocols

1 day
1 visit (in-person)

Postoperative Monitoring

Participants' pain scores and opioid usage are evaluated using a pain journal and electronic medical records

2 weeks
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Bupivacaine Hydrochloride-EPINEPHrine
  • Lidocaine Epinephrine
  • Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
Trial Overview The study tests if Exparel, when injected during surgery, reduces the need for opioid painkillers after thyroid and parathyroid surgeries. It aims to improve postoperative pain management.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Exparel InjectionExperimental Treatment1 Intervention
Thyroid and parathyroid surgery with local injection of lidocaine and epinephrine preincison and Exparel postincision
Group II: Bupivicaine HCLExperimental Treatment1 Intervention
Thyroid or parathyroid surgery with local injection of bupivicaine HCL and Epinephrine preincision.
Group III: Current PracticeActive Control1 Intervention
Thyroid or parathyroid surgery with local injection of lidocaine and epinephrine preincision, as is current practice.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Missouri-Columbia

Lead Sponsor

Trials
387
Recruited
629,000+

Findings from Research

In a study of 111 patients undergoing total thyroidectomy, bilateral superficial cervical plexus block with 0.75% ropivacaine, whether administered before or after surgery, did not improve postoperative pain management compared to no block.
There were no significant differences in morphine requirements, pain intensity scores, or overall opioid consumption among the groups, indicating that this method of analgesia may not be effective for enhancing pain relief in this surgical context.
The bilateral superficial cervical plexus block with 0.75% ropivacaine administered before or after surgery does not prevent postoperative pain after total thyroidectomy.Herbland, A., Cantini, O., Reynier, P., et al.[2022]
In a retrospective analysis of 575 subjects across 6 clinical trials, liposome bupivacaine showed a similar safety profile to both bupivacaine HCl and normal saline, with 76% of liposome bupivacaine recipients experiencing adverse events (AEs).
The most common AEs for liposome bupivacaine included nausea and hypesthesia, and serious AEs occurred in 8% of subjects, indicating that the side effects are likely related to the surgical procedure rather than the medication itself.
Safety and Side Effect Profile of Liposome Bupivacaine (Exparel) in Peripheral Nerve Blocks.Ilfeld, BM., Viscusi, ER., Hadzic, A., et al.[2022]
Liposomal bupivacaine (LB) is safe for use in pediatric patients and significantly improves pain control after pharyngoplasty, as evidenced by lower pain scores compared to those receiving standard lidocaine.
Patients treated with LB had earlier oral intake, required fewer opioids, and were discharged from the hospital nearly 2 days earlier than those in the control group, highlighting its efficacy in postoperative recovery.
Extended Release Liposomal Bupivacaine Injection (Exparel) for Early Postoperative Pain Control Following Pharyngoplasty.Day, KM., Nair, NM., Griner, D., et al.[2018]

References

The bilateral superficial cervical plexus block with 0.75% ropivacaine administered before or after surgery does not prevent postoperative pain after total thyroidectomy. [2022]
Randomized controlled trial on the efficacy of bilateral superficial cervical plexus block in thyroidectomy. [2022]
3.China (Republic : 1949- )pubmed.ncbi.nlm.nih.gov
Bupivacaine application reduces post thyroidectomy pain: Cerrahpasa experience. [2020]
Prospective, randomized controlled trial on use of ropivacaine after robotic thyroid surgery: Effects on postoperative pain. [2018]
Evaluation of etidocaine hydrochloride for local anesthesia and postoperative pain control in oral surgery. [2019]
Safety and Side Effect Profile of Liposome Bupivacaine (Exparel) in Peripheral Nerve Blocks. [2022]
Safety and Efficacy of Long-Acting Liposomal Bupivacaine Plus Bupivacaine Hydrochloride for Dorsal Penile Block During Ambulatory Pediatric Urologic Surgery. [2023]
Extended Release Liposomal Bupivacaine Injection (Exparel) for Early Postoperative Pain Control Following Pharyngoplasty. [2018]
Recent advances in incorporation of local analgesics in postsurgical pain pathways. [2014]
10.United Statespubmed.ncbi.nlm.nih.gov
Local infiltration of liposome bupivacaine in orthopedic trauma patients: case-based reviews. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security